Addex Therapeutics (ADXN) Change in Receivables (2019 - 2026)
Addex Therapeutics (ADXN) posted Change in Receivables of -$15.2 billion for Q1 2026, down 163.41% sequentially from $24.0 billion in Q2 2025, and up 31.13% YoY from -$11.6 billion in Q1 2025.
Addex Therapeutics (ADXN) Change in Receivables (2019 - 2026) Analysis & Trends
Addex Therapeutics has reported Change in Receivables for 8 years, with the latest figure at -$15.2 billion in Q1 2026.
- Quarterly Change in Receivables rose 31.13% year-over-year to -$15.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $410.6 billion (up 2124.92% YoY) and the FY2025 annual result came in at -$5516.8, down 105.21% from the prior year.
- Change in Receivables slipped to -$15.2 billion in Q1 2026 per ADXN's latest filing, from $24.0 billion in the prior quarter.
- Over five years, Change in Receivables peaked at $423.9 billion in Q4 2024 and troughed at -$428.7 billion in Q3 2024.
- A 5-year average of -$1.4 billion and a median of $35308.0 in 2022 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 492631036.91% in 2023, down 211928263.42% in 2023.
- Over 5 years, Change in Receivables stood at -$123736.4 in 2022, then sank by 211928263.42% to -$262.2 billion in 2023, then jumped by 261.67% to $423.9 billion in 2024, then slumped by 94.34% to $24.0 billion in 2025, then tumbled by 163.41% to -$15.2 billion in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$15.2 billion, $24.0 billion, and -$22.1 billion for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -15.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.20 Bn |
| Mar 31, 2026 | -15.20 Bn |
| Jun 30, 2025 | 23.97 Bn |
| Jun 30, 2025 | 23.97 Bn |
| Mar 31, 2025 | -22.08 Bn |
| Mar 31, 2025 | -22.08 Bn |
| Dec 31, 2024 | 423.95 Bn |
| Dec 31, 2024 | 423.95 Bn |
| Sep 30, 2024 | -428.66 Bn |
| Sep 30, 2024 | -428.66 Bn |
| Jun 30, 2024 | 6.51 Bn |
| Jun 30, 2024 | 6.51 Bn |
| Mar 31, 2024 | -6.74 Bn |
| Mar 31, 2024 | -6.74 Bn |
| Dec 31, 2023 | -262.23 Bn |
| Dec 31, 2023 | -262.23 Bn |
| Sep 30, 2023 | 80.82 Bn |
| Sep 30, 2023 | 80.82 Bn |
| Jun 30, 2023 | 179.30 Bn |
| Jun 30, 2023 | 179.30 Bn |